**Summary**
PureTech Health plc, a biotherapeutics company, announced its final results for the year ended December 31, 2025, highlighting a refined strategy and disciplined execution to unlock value from its portfolio. The company reported level cash, cash equivalents, and short-term investments of $277.1 million as of December 31, 2025, with an operational runway through the end of 2028. Key achievements include advancing Celea Therapeutics deupirfenidone to Phase 3 readiness for idiopathic pulmonary fibrosis, positive clinical results for Gallop Oncologys LYT-200 in myeloid malignancies, and Seaport Therapeutics progress in neuropsychiatric disorders. PureTech also announced its intention to voluntarily delist from Nasdaq and focus on the London Stock Exchange, aiming for a leaner, more focused business with increased shareholder returns. The companys 2026 AGM is scheduled for June 10, 2026, with a continued emphasis on advancing promising programs and maintaining a capital-efficient model.
| Financial Metric | 2024 | 2025 | Change |
|---|---|---|---|
| Total Revenue ($ million) | 4.8 | 4.7 | (0.1) or -2% | tr>
| General and Administrative Expenses ($ million) | 71.5 | 46.6 | (24.9) or -35% |
| Research and Development Expenses ($ million) | 69.5 | 56.6 | (12.9) or -19% |
| Net Finance Income/Costs ($ million) | 4.8 | (32.7) | (37.5) or -786% |
| Cash and Cash Equivalents ($ million) | 280.6 | 252.5 | (28.1) or -10% |
| Short-term Investments ($ million) | 86.7 | 24.8 | (61.9) or -71% |
| Total Debt (Sale of Future Royalties Liability) ($ million) | 143.2 | 183.7 | 40.5 or 28% |